Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshimi Takano

Showing results (31-40 of 178) with videos related to

Pageof 18
Sort By:
Clinical Breast Cancer|August 4, 2018
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2<sup>-</sup> Early-stage Breast CancerTakashi Kuwayama, Seigo Nakamura, Naoki Hayashi, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2012
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapyKohei Shitara, Satoshi Yuki, Kentaro Yamazaki, et al.
Oncology Letters|September 18, 2023
Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case reportYoichi Aoki, Yosuke Inoue, Naoki Sasahira, et al.
Breast Cancer (Tokyo, Japan)|January 23, 2018
Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution studyYukinori Ozaki, Yuko Tanabe, Nobuko Tamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 17, 2020
[Hypopituitarism]Taro Yamanaka, Keita Tatsushima, Chihiro Kondoh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 11, 2015
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapyYoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, et al.
Journal of Pharmaceutical Health Care and Sciences|January 30, 2018
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factorsTetsuya Sasaki, Yasuhisa Kato, Atsushi Sato, et al.
BMC Cancer|January 23, 2015
Ewing sarcoma of the liver with multilocular cystic mass formation: a case reportYukinori Ozaki, Yuji Miura, Shigehiro Koganemaru, et al.
BMC Cancer|February 7, 2018
Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot studyYukinori Ozaki, Junichi Shindoh, Wataru Gonoi, et al.
International Journal of Nanomedicine|October 11, 2022
Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast CancerYoshimasa Kosaka, Toshiaki Saeki, Toshimi Takano, et al.
Pageof 18

Showing results (31-40 of 178) with videos related to

Sort By:
Pageof 18
Clinical Breast Cancer|August 4, 2018
Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2<sup>-</sup> Early-stage Breast CancerTakashi Kuwayama, Seigo Nakamura, Naoki Hayashi, et al.
Journal of Cancer Research and Clinical Oncology|December 20, 2012
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapyKohei Shitara, Satoshi Yuki, Kentaro Yamazaki, et al.
Oncology Letters|September 18, 2023
Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case reportYoichi Aoki, Yosuke Inoue, Naoki Sasahira, et al.
Breast Cancer (Tokyo, Japan)|January 23, 2018
Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution studyYukinori Ozaki, Yuko Tanabe, Nobuko Tamura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 17, 2020
[Hypopituitarism]Taro Yamanaka, Keita Tatsushima, Chihiro Kondoh, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 11, 2015
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapyYoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, et al.
Journal of Pharmaceutical Health Care and Sciences|January 30, 2018
A questionnaire survey of pharmacists regarding the clinical practice guidelines for the appropriate use of granulocyte-colony stimulating factorsTetsuya Sasaki, Yasuhisa Kato, Atsushi Sato, et al.
BMC Cancer|January 23, 2015
Ewing sarcoma of the liver with multilocular cystic mass formation: a case reportYukinori Ozaki, Yuji Miura, Shigehiro Koganemaru, et al.
BMC Cancer|February 7, 2018
Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot studyYukinori Ozaki, Junichi Shindoh, Wataru Gonoi, et al.
International Journal of Nanomedicine|October 11, 2022
Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast CancerYoshimasa Kosaka, Toshiaki Saeki, Toshimi Takano, et al.
Pageof 18